Eos Energy Enterprises Inc vs GeneDx Holdings Corp — how do they compare? Eos Energy Enterprises Inc trades at $3.96 (market cap $1.55B), while GeneDx Holdings Corp trades at $62.71 (market cap $1.96B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | WGS | |
|---|---|---|
Market Cap | $1.55B | $1.96B |
Sector | Energy | Technology |
52-Week High | $19.19 | $167.51 |
52-Week Low | $4.29 | $34.51 |
Enterprise Value | $1.79B | $1.96B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.99, down 6.99% on the day, reflecting a challenging fundamental picture with significant losses. The company reported a net loss of $969.65M on $114.20M revenue for 2025, though recent Q1 2026 results showed a surprise EPS beat. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while the stock is consolidating near a key $4 support level. Recent news highlights accelerating commercial execution, including a major project selection for the Golden Dome initiative and preliminary Q2 2026 results pointing to record quarterly revenue and backlog.
The outlook presents a high-risk, high-reward scenario. Significant revenue acceleration and project backlog growth offer potential upside, supported by a consensus analyst price target of $9.00 (125% upside). However, deep negative margins, substantial cash burn, and a highly leveraged balance sheet with 91.87% debt-to-asset ratio pose severe financial risks. Investment success hinges on the company's ability to achieve manufacturing scale and path to profitability in the competitive energy storage market.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →